Company profile: BioAegis Therapeutics
1.1 - Company Overview
Company description
- Provider of plasma gelsolin-based therapeutics for infectious, inflammatory and degenerative diseases. Offers recombinant human plasma gelsolin (rhu-pGSN) to restore depleted levels, regulate inflammation and enhance immune response without immunosuppression; ARDS treatment; host-directed therapeutics; >40-patent IP; clinical trials and research collaborations.
Products and services
- Recombinant Human Plasma Gelsolin (rhu-pGSN): A protein-based therapeutic restoring depleted plasma gelsolin to regulate inflammation and enhance immune responses without causing immunosuppression across infectious, inflammatory, and degenerative indications
- Host-Directed Therapeutics (HDT): Host-directed therapeutics enhancing the body's natural immune responses to reduce excessive inflammation and optimize immune reactivity, effective against multiple pathogens including drug-resistant strains
- Acute Respiratory Distress Syndrome (ARDS) Treatment: rhu-pGSN-based therapy addressing severe inflammatory responses in ARDS to reduce mortality and improve outcomes without immunosuppression
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to BioAegis Therapeutics
Jaguar Health
HQ: United States
Website
- Description: Provider of plant-based prescription medicines for urgent global health needs, including Crofelemer, an oral therapy for noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy, being studied for cancer therapy–related diarrhea and short bowel syndrome with intestinal failure; Canalevia-CA1 for chemotherapy-induced diarrhea in dogs; and NP-300, an investigational antisecretory for cholera-related diarrhea.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Jaguar Health company profile →
DeepUll
HQ: Spain
Website
- Description: Provider of a biotech diagnostic system for early-stage sepsis that rapidly identifies pathogens and delivers an antibiogram within hours, leveraging patient immunological and functional data.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full DeepUll company profile →
LigoCyte Pharmaceuticals
HQ: United States
Website
- Description: Provider of vaccines and monoclonal antibodies for gastrointestinal and respiratory indications, developing novel immunomodulatory drug compounds that modify immune responses by targeting cell binding interactions for the treatment of inflammatory and infectious diseases.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full LigoCyte Pharmaceuticals company profile →
Biophytis
HQ: France
Website
- Description: Provider of clinical-stage therapeutics for metabolic and age-related diseases, developing orally administered small molecules including Ruvembri for sarcopenia via MAS receptor activation to stimulate respiratory and motor functions, BIO101 for neuromuscular diseases (sarcopenia, DMD) and in a phase 2 obesity study with GLP-1 receptor agonists, and Macuneos (BIO201) for retinal diseases (dry AMD, Stargardt).
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Biophytis company profile →
Helix BioMedix
HQ: United States
Website
- Description: Provider of skin health consumer products and bioactive peptide solutions for dermatological and personal care, including a proprietary peptide library with antimicrobial, anti-inflammatory and wound healing properties; SmartPeptides to enhance skin appearance; Oligopeptide-10 for acne; Palmitoyl Hexapeptide-14 and Hexapeptide-21 to stimulate collagen; and HB4208, a preclinical DNA Damage Response enzyme for Xeroderma Pigmentosum.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Helix BioMedix company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for BioAegis Therapeutics
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to BioAegis Therapeutics
2.2 - Growth funds investing in similar companies to BioAegis Therapeutics
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for BioAegis Therapeutics
4.2 - Public trading comparable groups for BioAegis Therapeutics
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →